Rezolute, Inc. (RZLT) intrinsic value & 10-year financials

Rezolute, Inc. (RZLT) has no Graham intrinsic value right now because the formula needs positive earnings.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$3.58
Market cap
$272.1M
Revenue (FY2025)
—
ROIC (10-yr avg)
518.1%
Free cash flow (FY2025)
—

RZLT 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 — -$74.4M -$0.98 — — -131.8%
FY2024 — -$68.5M -$1.33 — — -91.3%
FY2023 — -$51.8M -$1.01 -$44.6M — -110.6%
FY2022 — -$41.1M -$2.32 — — 5065.7%
FY2021 — -$20.9M -$2.72 — — -1567.0%
FY2020 — -$20.3M — -$24.2M — 672.2%
FY2019 — -$30.4M — -$15.4M — 432.3%
FY2018 — -$29.9M — -$14.1M — 1317.0%
FY2017 — -$20.3M — — — -234.9%
FY2016 — -$14.9M — — — -170.4%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Rezolute, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

Rezolute, Inc. has historically struggled to out-earn its cost of capital, averaging just -27.9% ROIC.

Rezolute, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Rezolute, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.

RZLT stock: frequently asked questions

What is the intrinsic value of Rezolute, Inc. (RZLT) stock?

Graham's formula only works with positive earnings. Rezolute, Inc. reported diluted EPS of -$0.98 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

What is RZLT's return on invested capital?

Average ROIC over the last 10 fiscal years was 518.1%, and average return on equity was 27.8%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this RZLT data come from?

From Rezolute, Inc.'s annual 10-K filings on SEC EDGAR, most recently filed May 12, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks